Weight Loss : Clinical trials show significant weight loss with semaglutide, but most studies use higher doses than those found in Ozempic
Current FDA-approved weekly injectable GLP-1 options include: Ozempic (semaglutide, Novo Nordisk) for type 2 diabetes Wegovy (semaglutide, Novo Nordisk) for chronic weight management Mounjaro (tirzepatide, Lilly) for type 2 diabetes Zepbound (tirzepatide, Lilly) for chronic weight management Rybelsus (oral semaglutide, Novo Nordisk) for type 2 diabetes Foundayo (orforglipron, Lilly) oral, for weight management (approved April 2026) For patients who struggle specifically with weekly injections, the most practical currently available option is Foundayo (orforglipron) an oral pill requiring no injection at all
With 120 capsules per bottle, it provides up to 40 servings, giving you a dependable option to carry through your fitness goals
Mia Bonta Legislator I'll ask all my questions and then you can the second is, has there been any consideration or how do the are there any expedited processes for existing organizations during this two year moratorium for new PACE programs that we need to be aware of
